Vistagen Therapeutics (VTGN) Payables (2011 - 2026)
Vistagen Therapeutics (VTGN) posted Payables of $1.5 million for Q1 2026, down 8.63% sequentially from $1.7 million in Q4 2025, and up 135.07% YoY from $653000.0 in Q1 2025.
Vistagen Therapeutics (VTGN) Payables (2011 - 2026) Analysis & Trends
Vistagen Therapeutics has reported Payables for 15 years, with the latest figure at $1.5 million in Q1 2026.
- Quarterly Payables rose 135.07% year-over-year to $1.5 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.5 million (up 135.07% YoY) and the FY2026 annual result came in at $1.5 million, up 135.07% from the prior year.
- Payables eased to $1.5 million in Q1 2026 per VTGN's latest filing, from $1.7 million in the prior quarter.
- Over five years, Payables peaked at $3.7 million in Q3 2022 and troughed at $653000.0 in Q1 2025.
- A 5-year average of $1.8 million and a median of $1.5 million in 2024 frame the typical range for Payables.
- The sharpest annual moves came in 2022 and 2023: Payables surged 112005.56% in 2022, then sank 64.61% in 2023.
- Over 5 years, Payables stood at $2.0 million in 2022, then retreated by 13.92% to $1.7 million in 2023, then tumbled by 40.18% to $1.0 million in 2024, then soared by 61.69% to $1.7 million in 2025, then retreated by 8.63% to $1.5 million in 2026.
- According to Business Quant data, Payables over the past three periods registered $1.5 million, $1.7 million, and $2.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Payables (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.81 Bn | 131.96 Bn | 2.84 Bn | 429.50 Mn |
| 2 | Regeneron Pharmaceuticals | 86.56 Bn | 78.56 Bn | 3.93 Bn | 1.16 Bn |
| 3 | Argenx Se | 65.72 Bn | 60.53 Bn | 1.37 Bn | 1.52 Bn |
| 4 | Moderna | 58.75 Bn | 53.61 Bn | 52.00 Mn | 167.00 Mn |
| 5 | BeOne Medicines | 42.16 Bn | 37.06 Bn | 1.53 Bn | 470.30 Mn |
| 6 | Alnylam Pharmaceuticals | 31.76 Bn | 28.45 Bn | 992.69 Mn | 108.02 Mn |
| 7 | BioNTech SE | 28.59 Bn | 10.19 Bn | 668.28 Mn | 622.65 Mn |
| 8 | Insmed | 27.63 Bn | 26.47 Bn | 358.27 Mn | 428.93 Mn |
| 9 | Royalty Pharma | 27.24 Bn | 26.40 Bn | - | 35.57 Mn |
| 10 | Vistagen Therapeutics | 10.42 Mn | 10.42 Mn | - | 1.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.54 Mn |
| Dec 31, 2025 | 1.68 Mn |
| Sep 30, 2025 | 2.49 Mn |
| Jun 30, 2025 | 1.42 Mn |
| Mar 31, 2025 | 653,000.00 |
| Dec 31, 2024 | 1.04 Mn |
| Sep 30, 2024 | 715,000.00 |
| Jun 30, 2024 | 1.21 Mn |
| Mar 31, 2024 | 1.55 Mn |
| Dec 31, 2023 | 1.74 Mn |
| Sep 30, 2023 | 1.31 Mn |
| Jun 30, 2023 | 2.41 Mn |
| Mar 31, 2023 | 2.58 Mn |
| Dec 31, 2022 | 2.02 Mn |
| Sep 30, 2022 | 3.69 Mn |
| Jun 30, 2022 | 1.05 Mn |
| Mar 31, 2022 | 2.76 Mn |
| Dec 31, 2021 | 1,800.00 |
| Sep 30, 2021 | 2.66 Mn |
| Jun 30, 2021 | 2.32 Mn |